The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Catherine Lai,1 Adrese Michael Kandahari,1 Chaitra Ujjani2 1Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USA; 2Seattle Cancer Care Alliance, Fred Hutchinson CRC, University of Washington, Seattle, WA, USACorrespondence: Catherine LaiLombardi Comprehen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lai C, Kandahari AM, Ujjani C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	antibody-drug conjugate brentuximab vedotin cd30 hodgkin lymphoma immunotherapy. Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/8d0f2aa8840b4083b1f665551c3fda37
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8d0f2aa8840b4083b1f665551c3fda37
record_format	dspace
spelling	oai:doaj.org-article:8d0f2aa8840b4083b1f665551c3fda372021-12-02T11:59:56ZThe Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma1179-9889https://doaj.org/article/8d0f2aa8840b4083b1f665551c3fda372019-12-01T00:00:00Zhttps://www.dovepress.com/the-evolving-role-of-brentuximab-vedotin-in-classical-hodgkin-lymphoma-peer-reviewed-article-BLCTThttps://doaj.org/toc/1179-9889Catherine Lai,1 Adrese Michael Kandahari,1 Chaitra Ujjani2 1Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USA; 2Seattle Cancer Care Alliance, Fred Hutchinson CRC, University of Washington, Seattle, WA, USACorrespondence: Catherine LaiLombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USATel +1-202-444-3735Fax +1-202-444-0939Email Catherine.lai@gunet.georgetown.eduAbstract: The arrival of the CD30 directed antibody-drug conjugate, brentuximab vedotin (BV), has altered the approach to patients with classical Hodgkin lymphoma. Since initial approval in 2011, BV has been extensively studied in previously untreated and relapsed/refractory patients. Treatment indications for the antibody-drug conjugate have been expanded from the previously treated population to include maintenance therapy after autologous stem cell transplantation and recently, combination with chemotherapy in newly diagnosed advanced stage patients. This article will review the evolution of BV in classical Hodgkin lymphoma, detailing the studies that led to the approved indications and discussion of recent trials in combination with chemotherapy and immunotherapy.Keywords: antibody-drug conjugate, brentuximab vedotin, CD30, immunotherapy, classical Hodgkin lymphoma, novel therapiesLai CKandahari AMUjjani CDove Medical Pressarticleantibody-drug conjugatebrentuximab vedotincd30hodgkin lymphomaimmunotherapy.Diseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol Volume 9, Pp 63-71 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	antibody-drug conjugate brentuximab vedotin cd30 hodgkin lymphoma immunotherapy. Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	antibody-drug conjugate brentuximab vedotin cd30 hodgkin lymphoma immunotherapy. Diseases of the blood and blood-forming organs RC633-647.5 Lai C Kandahari AM Ujjani C The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
description	Catherine Lai,1 Adrese Michael Kandahari,1 Chaitra Ujjani2 1Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USA; 2Seattle Cancer Care Alliance, Fred Hutchinson CRC, University of Washington, Seattle, WA, USACorrespondence: Catherine LaiLombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USATel +1-202-444-3735Fax +1-202-444-0939Email Catherine.lai@gunet.georgetown.eduAbstract: The arrival of the CD30 directed antibody-drug conjugate, brentuximab vedotin (BV), has altered the approach to patients with classical Hodgkin lymphoma. Since initial approval in 2011, BV has been extensively studied in previously untreated and relapsed/refractory patients. Treatment indications for the antibody-drug conjugate have been expanded from the previously treated population to include maintenance therapy after autologous stem cell transplantation and recently, combination with chemotherapy in newly diagnosed advanced stage patients. This article will review the evolution of BV in classical Hodgkin lymphoma, detailing the studies that led to the approved indications and discussion of recent trials in combination with chemotherapy and immunotherapy.Keywords: antibody-drug conjugate, brentuximab vedotin, CD30, immunotherapy, classical Hodgkin lymphoma, novel therapies
format	article
author	Lai C Kandahari AM Ujjani C
author_facet	Lai C Kandahari AM Ujjani C
author_sort	Lai C
title	The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
title_short	The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
title_full	The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
title_fullStr	The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
title_full_unstemmed	The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
title_sort	evolving role of brentuximab vedotin in classical hodgkin lymphoma
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/8d0f2aa8840b4083b1f665551c3fda37
work_keys_str_mv	AT laic theevolvingroleofbrentuximabvedotininclassicalhodgkinlymphoma AT kandahariam theevolvingroleofbrentuximabvedotininclassicalhodgkinlymphoma AT ujjanic theevolvingroleofbrentuximabvedotininclassicalhodgkinlymphoma AT laic evolvingroleofbrentuximabvedotininclassicalhodgkinlymphoma AT kandahariam evolvingroleofbrentuximabvedotininclassicalhodgkinlymphoma AT ujjanic evolvingroleofbrentuximabvedotininclassicalhodgkinlymphoma
_version_	1718394762494476288

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Ejemplares similares